These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26546899)

  • 1. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.
    Alsahebfosoul F; Zavaran Hosseini A; Salehi R; Etemadifar M; Esmaeil N; Jamshidian A
    Iran J Allergy Asthma Immunol; 2015 Jun; 14(3):298-305. PubMed ID: 26546899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cells upregulate Treg cells via sHLA-G in SLE patients.
    Chen C; Liang J; Yao G; Chen H; Shi B; Zhang Z; Zhao C; Zhang H; Sun L
    Int Immunopharmacol; 2017 Mar; 44():234-241. PubMed ID: 28129605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Caniatti ML; Baldi E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2007 Dec; 192(1-2):219-25. PubMed ID: 17997167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients.
    Bjerg L; Brosbøl-Ravnborg A; Tørring C; Dige A; Bundgaard B; Petersen T; Höllsberg P
    J Neuroimmunol; 2012 Aug; 249(1-2):76-82. PubMed ID: 22608884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
    Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
    Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
    Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation.
    Morandi F; Venturi C; Rizzo R; Castellazzi M; Baldi E; Caniatti ML; Tola MR; Granieri E; Fainardi E; Uccelli A; Pistoia V
    J Neuroimmune Pharmacol; 2013 Sep; 8(4):944-55. PubMed ID: 23625177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
    Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
    CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis.
    Rizzo R; Bortolotti D; Fredj NB; Rotola A; Cura F; Castellazzi M; Tamborino C; Seraceni S; Baldi E; Melchiorri L; Tola MR; Granieri E; Baricordi OR; Fainardi E
    Hum Immunol; 2012 Nov; 73(11):1140-6. PubMed ID: 22922127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human leukocyte antigen-G and regulatory T cells during specific immunotherapy for pollen allergy.
    Sørensen AE; Johnsen CR; Dalgaard LT; Würtzen PA; Kristensen B; Larsen MH; Ullum H; Søes-Petersen U; Hviid TV
    Int Arch Allergy Immunol; 2013; 162(3):237-52. PubMed ID: 24022071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study.
    Minagar A; Adamashvili I; Kelley RE; Gonzalez-Toledo E; McLarty J; Smith SJ
    J Neuroinflammation; 2007 Jul; 4():16. PubMed ID: 17601341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
    Rodi M; Dimisianos N; de Lastic AL; Sakellaraki P; Deraos G; Matsoukas J; Papathanasopoulos P; Mouzaki A
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP
    Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
    Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
    Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
    Minagar A; Adamashvilli I; Jaffe SL; Glabus MF; Gonzalez-Toledo E; Kelley RE
    Ann N Y Acad Sci; 2005 Jun; 1051():111-20. PubMed ID: 16126950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.